Home / radionuclide

radionuclide

April 28, 2025

Total body PET imaging: the changing radionuclide imaging landscape in the UK

Non-invasive radionuclide imaging has transformed clinical practice through enabling earlier diagnosis than before, more comprehensive staging, and monitoring of disease progression and therapy response. The quantitative nature of PET and widespread availability of standard radiopharmaceuticals, in particular [18F]FDG, have contributed to PET’s success. However, until recently, in order to capture information ‘from eyes to thighs’, […]

Professor Alexander Hammers; Dr Samantha Terry

King's College London

Read Article

October 13, 2021

Improving target volume delineation for 3D image-based dosimetry in PRRT

Peptide receptor radionuclide therapy (PRRT) using radiolabelled somatostatin analogues is currently the most effective molecular radiotherapy (MRT) treatment for patients who suffer from neuroendocrine tumours (NET) with metastasised disease. In PRRT the treatment is systemic and the most frequent treatment protocol is to administer 7.4GBq of Lu-177 up to four times with a six to […]

Dr Emiliano Spezi, Dr Salvatore Berenato

Cardiff University, Velindre Cancer Centre

Read Article

October 13, 2021

The contribution of hybrid imaging to radionuclide therapy

Radionuclide therapy is a rapidly evolving field considered a safe and effective targeted approach to treating many types of cancer. Radiation is systemically or locally delivered using pharmaceuticals that either bind preferentially to cancer cells or accumulate at the site of treatment by physiological mechanisms. Almost all radionuclides used in radionuclide therapy emit photons that […]

Carla Aberu, Paul Gape, Jan Taprogge, Glen Fluxx

The Royal Marsden Hospital, The Institute of Cancer Research

Read Article

October 16, 2019

SPECT/CT in oncology

Radionuclide imaging can demonstrate whole body functional/metabolic information and plays an important role in oncology clinical and research practice. It is integral to many clinical pathways, assisting in diagnosis and staging, pre-operative localisation, monitoring response and detecting recurrence. However, planar scintigraphy and SPECT lack anatomical and structural details resulting in low specificity and sensitivity with […]

Dr Fraser Hendry, Dr Sai Han

Glasgow Royal Infirmary, Gartnavel General Hospital

Read Article

August 14, 2018

The changing landscape of molecular radiotherapy

Radionuclide therapy is probably the only field of medicine that allows direct imaging of a drug as it is used to treat cancer. Radioiodine was first used over 70 years ago for the treatment of benign thyroid disease and thyroid cancer. Levels of activity to administer were determined empirically, influenced largely by limitations in supply […]

Dr Glenn Flux

Royal Marsden Hospital NHS Foundation Trust

Read Article

August 19, 2016

Newer radionuclide therapies

Radionuclide therapy (RNT), also known as molecular radiotherapy (MRT), utilises unsealed ionising radiation to target particular tissues. RNT depends on the properties of the radionuclides and tracer conjugates that selectively binds to cell receptors. The majority of radionuclides used in RNT are beta (β)-particles, although there is an established role and also emerging applications using […]

Dr Francis Sundram, Dr Eleonora Manca

University Hospital Southampton NHS Foundation Trust

Read Article

August 14, 2015

SPECT/CT imaging of bone

The skeleton is a metabolically active organ that undergoes continuous remodelling throughout life. Normal healthy bones are dynamic structures with inherent basal levels of turnover sustained by balanced osteoblastic and osteoclastic activity. Increased bone turnover (ie osteoblastic activity) is the central mechanism of attempts at bone healing in case of any insult, whether it is […]

Dr Zubair Ali Khan, Dr Abdul-Aziz Al-Sugair

Western General Hospital, King Faisal Specialist Hospital and Research Centre

Read Article

April 17, 2015

Radionuclide imaging in epilepsy

Epilepsy is one of the most frequent chronic neurological disorders, with an incidence of 50/100,000/year and a prevalence of 0.5-1% in Western society. One third of patients with epilepsy have seizures that do not respond to medical treatment leading to cognitive decline, poor quality of life, high societal costs and significantly increased mortality including sudden […]

Dr Maria Vittoria Mattoli, Dr Francesco Fraioli, Dr Beate Diehl

University College London Hospitals NHS Foundation Trust, Universita Cattolica del Sacro Cuore, University College London

Read Article